Chemotherapy-Induced Nausea and Vomiting

New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of patients at risk, and the availability of new antiemetic agents have all contributed to substantial improvements in emetic control. This review focuses on our current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacologic interventions in its prevention and treatment. This review focuses on our current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacologic interventions in its prevention and treatment. The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past two decades. The development of effective means to prevent nausea and vomiting arising from chemotherapy serves as one of the most important examples of this progress. Patients beginning cancer treatment consistently list chemotherapy-induced nausea and vomiting as one of their greatest fears. 1 , 2 Inadequately controlled emesis impairs functional activity and quality of life for patients, increases the use of health care resources, and may occasionally compromise adherence to treatment. 3 – 5 New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of the risk . . .